Study to Assess L-Carnitines Kidney Protection in Patients Receiving Cisplatin Chemotherapy

What this Trial Is About

Researchers are evaluating whether L-carnitine can protect the kidneys from damage caused by cisplatin, a chemotherapy drug used to treat various solid tumors. Cisplatin is effective but can cause nephrotoxicity in 25-35% of patients due to its harmful effects on kidney tubules, oxidative stress, and inflammation. This study aims to understand if L-carnitines antioxidant and anti-inflammatory properties can reduce this kidney damage in patients receiving cisplatin-based chemotherapy. Participants will be randomly assigned to one of two groups one group will receive the standard cisplatin chemotherapy along with L-carnitine 350 mg taken orally three times daily, while the other group will receive the same chemotherapy with placebo tablets that look identical to the L-carnitine. This phase 2 trial uses a double-blind design, meaning neither participants nor researchers know which treatment each participant receives. During the study, participants kidney function will be closely monitored by measuring changes in serum creatinine and creatinine clearance before chemotherapy cycles. Researchers will also evaluate safety and side effects. The study includes adults aged 18 to 75 years who are newly diagnosed with cancer and scheduled for at least three cycles of cisplatin chemotherapy. Participation will last through the chemotherapy treatment period, with ongoing assessments to track kidney health and treatment effects.

L-Carnitine Protective Effect in Nephrotoxicity